CD1D and atherosclerosis: Since reduced lipid antigen presentation may limit atherosclerosis advancement toward a more complex stage [91], myeloid-derived apoE2 may accelerate atherosclerosis during the early phase of foam cell formation and deposition, but impedes atherosclerosis advancement to the complex lesion stage similar to that observed in hyperlipidemic CD1d−/− mice [93].